MORRISVILLE – Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, has signed an exclusive collaboration and license agreement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The deal could be worth up to $818 million.
The companies will team up to develop, manufacture and commercialize a product targeting a key bacterial pathogen for the potential treatment of infections of the respiratory tract and other organ systems.
Under the terms of the agreement, Locus will receive $20 million in initial payments and is eligible to receive up to $798 million in potential future development and commercial milestone payments and royalties on any product sales.
Locus is developing what is known as Type I CRISPR-Cas3-enhanced bacteriophage (“crPhage”) therapeutics.